Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
106.41 +0.90 (+0.85%) 04/23/25 [NASDAQ]
106.28 x 36 106.30 x 47
Realtime by (Cboe BZX)
106.28 x 36 106.30 x 47
Realtime 106.38 -0.03 (-0.03%) 16:03 ET
Quote Overview for Wed, Apr 23rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
105.39
Day High
106.63
Open 105.95
Previous Close 105.51 105.51
Volume 7,714,489 7,714,489
Avg Vol 9,161,200 9,161,200
Stochastic %K 45.96% 45.96%
Weighted Alpha +58.68 +58.68
5-Day Change +0.47 (+0.44%) +0.47 (+0.44%)
52-Week Range 62.07 - 119.96 62.07 - 119.96
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 131,377,152
  • Shares Outstanding, K 1,245,163
  • Annual Sales, $ 28,754 M
  • Annual Income, $ 480,000 K
  • EBIT $ 1,662 M
  • EBITDA $ 4,429 M
  • 60-Month Beta 0.32
  • Price/Sales 4.52
  • Price/Cash Flow 15.19
  • Price/Book 6.76

Options Overview Details

View History
  • Implied Volatility 33.02% ( -1.31%)
  • Historical Volatility 26.68%
  • IV Percentile 94%
  • IV Rank 47.04%
  • IV High 49.97% on 04/08/25
  • IV Low 17.95% on 11/07/24
  • Put/Call Vol Ratio 0.99
  • Today's Volume 8,043
  • Volume Avg (30-Day) 9,968
  • Put/Call OI Ratio 1.04
  • Today's Open Interest 221,203
  • Open Int (30-Day) 236,772

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 1.75
  • Number of Estimates 7
  • High Estimate 2.11
  • Low Estimate 1.35
  • Prior Year -1.32
  • Growth Rate Est. (year over year) +232.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
97.32 +9.07%
on 04/09/25
Period Open: 107.08
114.75 -7.49%
on 04/03/25
-0.93 (-0.87%)
since 03/21/25
3-Month
92.26 +15.06%
on 01/24/25
Period Open: 92.92
119.96 -11.51%
on 03/10/25
+13.23 (+14.24%)
since 01/23/25
52-Week
62.07 +71.02%
on 05/31/24
Period Open: 67.03
119.96 -11.51%
on 03/10/25
+39.12 (+58.36%)
since 04/23/24

Most Recent Stories

More News
Gilead Sciences (GILD) To Report Earnings Tomorrow: Here Is What To Expect

Gilead Sciences (GILD) To Report Earnings Tomorrow: Here Is What To Expect

GILD : 106.41 (+0.85%)
Stocks Set to Open Sharply Lower After Trump’s Push Against Powell, U.S. Economic Data and Tech Earnings in Focus

June S&P 500 E-Mini futures (ESM25) are down -1.09%, and June Nasdaq 100 E-Mini futures (NQM25) are down -1.23% this morning, pointing to a sharply lower open on Wall Street as U.S. President Donald Trump’s...

GOOGL : 155.25 (+2.50%)
AVGO : 176.67 (+4.18%)
VZ : 42.68 (-1.18%)
MRK : 78.69 (-0.36%)
TXN : 151.85 (+3.46%)
UNH : 427.96 (+0.18%)
ESM25 : 5,406.25 (+1.72%)
TSLA : 250.67 (+5.33%)
T : 27.19 (+0.85%)
IBM : 245.48 (+1.90%)
LLY : 829.24 (+0.21%)
NQM25 : 18,813.00 (+2.33%)
Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?

Biotech bigwig Gilead Sciences, Inc. GILD  is scheduled to report first-quarter 2025 results on April 24, after market close. The Zacks Consensus Estimate for sales and earnings is pegged at $6.83 billion...

MRK : 78.69 (-0.36%)
GILD : 106.41 (+0.85%)
GSK : 37.03 (+1.09%)
2 High-Yielding ETFs Retirees Can Safely Build Their Portfolios Around

Are you a retiree who's worried about the stock market? Now can be a concerning time to buy stocks, given the volatility. Where the economy is headed and what the tariff situation will look like over the...

MO : 58.54 (-0.48%)
VZ : 42.68 (-1.18%)
KO : 73.28 (-0.84%)
GCOW : 36.05 (-0.21%)
SCHW : 77.82 (+1.62%)
SCHD : 25.42 (-0.08%)
GILD : 106.41 (+0.85%)
PM : 167.93 (+2.32%)
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?

Gilead Sciences, Inc. GILD and Bristol Myers Squibb BMY are leading biotechnology companies with broad and diverse portfolios and a global footprint.Gilead Sciences is a pioneer in developing treatments...

MRK : 78.69 (-0.36%)
GILD : 106.41 (+0.85%)
BMY : 48.52 (-2.61%)
3 Reasons GILD is Risky and 1 Stock to Buy Instead

3 Reasons GILD is Risky and 1 Stock to Buy Instead

GILD : 106.41 (+0.85%)
NET : 112.80 (+5.61%)
Is Iovance Biotherapeutics a Millionaire-Maker?

Some investors see a striking similarity between lottery tickets and biotech stocks. In most cases, buying lottery tickets ends up being a waste of money. So does investing in most biotech stocks. But...

IOVA : 3.19 (-0.62%)
GILD : 106.41 (+0.85%)
Here's What to Expect From Gilead Sciences’ Next Earnings Report

Gilead Sciences is expected to announce its fiscal first-quarter earnings this month, and analysts forecast a robust triple-digit in its earnings.

XLV : 135.69 (+0.47%)
$SPX : 5,375.86 (+1.67%)
GILD : 106.41 (+0.85%)
Rule Breaker Investing: Essays From Yesterday, Vol. 7

It's time once again to dust off Motley Fool co-founder David Gardner's old writings and pull some lessons forward into the light of today. In this podcast we discuss buying stocks that you already own,...

NFLX : 1,049.03 (+0.83%)
NVDA : 102.52 (+3.67%)
FSLR : 131.20 (-3.07%)
BIDU : 87.46 (+2.82%)
BBY : 63.47 (+0.13%)
CHWY : 35.37 (-1.80%)
GILD : 106.41 (+0.85%)
AMGN : 277.78 (-0.22%)
AMZN : 180.54 (+4.25%)
KNSL : 491.66 (+0.81%)
2 Top Dividend Stocks That Could Set You Up for Life

With equity markets in shambles due to President Donald Trump's trade policies, now might be as good a time as any to invest in excellent dividend stocks.

ABBV : 176.95 (+1.82%)
GILD : 106.41 (+0.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 108.03
2nd Resistance Point 107.24
1st Resistance Point 106.37
Last Price 106.41
1st Support Level 104.71
2nd Support Level 103.92
3rd Support Level 103.05

See More

52-Week High 119.96
Last Price 106.41
Fibonacci 61.8% 97.85
Fibonacci 50% 91.01
Fibonacci 38.2% 84.18
52-Week Low 62.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective